Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on July 7, 2021. The filing addresses preliminary financial results for the quarter ended June 30, 2021. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
- Cash and Cash Equivalents: The company expects to report approximately $174 million as of June 30, 2021.
- Revenue, Profit, and Margins: The filing text does not provide clear values for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: No specific debt figures are disclosed in this report; liquidity is indicated by the estimated cash balance.
Material Changes
The filing does not provide comparative data for the prior period to determine material changes in financial metrics. The reported cash balance is an unaudited, preliminary estimate subject to change upon finalization of financial statements.
Guidance, Outlook, and Risks
Management expects the cash balance to be $174 million, though this is forward-looking and subject to risks and uncertainties. The company will participate in investor meetings using a corporate deck available on its website. The filing includes standard disclaimers regarding forward-looking statements and references risk factors detailed in the Form 10-Q for the period ended March 31, 2021.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-Q for the quarter ended June 30, 2021.
- Review the full financial statements for revenue, operating expenses, and net loss figures not included in this 8-K.
- Examine the "Risk Factors" section of the March 31, 2021 Form 10-Q for updated risks.
- Confirm the status of the independent registered public accounting firm's review of the financial statements.